Victor Tapson
Pulmonary Disease · Los Angeles, CANPI 1275693400
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $329,439 of the $514,384 with a category attached, or 64.0%. 24 manufacturers reported payments, led by Janssen Research & Development, LLC at 33.0% of the total. Reporting peaked in 2022 at $156,430 and has fallen 98.8% since, to $1,892 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $1670.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$170K
- Johnson & Johnson$165K
- United Therapeutics Corporation$53K
- Actelion Pharmaceuticals, Ltd$36K
- Daiichi Sankyo Inc.$19K
- Boston Scientific$17K
- plus $56K from 18 others
Across 34 payments — averaging $12,376 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$213K
- Merck$128K
- E.r. Squibb & Sons, L.L.C.$43K
- Daiichi Sankyo Inc.$31K
- United Therapeutics Corporation$5K
- Janssen Research & Development, LLC$2K
What the payments were for
- Consulting fees$329,43964%
- Speaking & faculty fees$139,43927%
- Travel & lodging$32,0226%
- Food & beverage$13,4843%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 21 | $169,828 |
| Johnson & Johnson | 121 | $164,882 |
| United Therapeutics Corporation | 47 | $52,724 |
| Actelion Pharmaceuticals, Ltd | 24 | $35,566 |
| Daiichi Sankyo Inc. | 1 | $18,810 |
| Boston Scientific | 2 | $16,969 |
| Actelion Pharmaceuticals US, Inc. | 11 | $13,121 |
| E.r. Squibb & Sons, L.L.C. | 6 | $12,581 |
| Pfizer | 4 | $6,866 |
| Biocompatibles, Inc. | 6 | $6,609 |
| Inari Medical, Inc. | 38 | $6,401 |
| EKOS Corporation | 4 | $4,595 |
| Janssen Scientific Affairs, LLC | 2 | $1,800 |
| Merck | 1 | $1,350 |
| Stryker | 5 | $691 |
| Angiodynamics, Inc. | 1 | $597 |
| Inquis Medical, Inc. | 3 | $249 |
| Imperative Care, Inc | 1 | $195 |
| Jubilant Draximage Inc. | 2 | $190 |
| Viz.ai, Inc. | 1 | $124 |
| AstraZeneca | 1 | $96 |
| Sandoz | 3 | $56 |
| Gilead | 2 | $47 |
| Genentech USA, Inc. | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$178,583
- TYVASO$20,042
- CLINICAL TRIAL PRODUCT$16,969
- NONE$13,708
- UPTRAVI$12,710
- EKOSONIC$10,975
- ELIQUIS$10,210
- ORENITRAM$7,505
- FLOWTRIEVER CATHETER, S$5,555
- CT THROMBECTOMY SYSTEM KIT$5,162
- REMODULIN$3,542
- FlowTriever$1,404
- ClotTriever$1,100
- AlphaVac$597
- Aventus$202
- SYMPHONY CATHETER$195
- Viz.AI LVO$124
- OPSUMIT$113
- DRAXIMAGE MAA$102
How this compares
$514,384 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 17 | $17,554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $164,882 | $17,55417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$1.3M
- Rajan SaggarLos Angeles$480K
- Igor BarjaktarevicLos Angeles$337K
- Scott OhLos Angeles$252K
- Christopher CooperLos Angeles$239K
- John BelperioLos Angeles$224K
- Robert StrieterLos Angeles$173K
- Roy ArtalLos Angeles$152K
- Donald TashkinLos Angeles$141K
- Jameel HouraniLos Angeles$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.